Get the Stockscreener App
1.70
15.00%
-0.2999
Immuron Limited Adr stock is traded at $1.70, with a volume of 21,162.
It is down -15.00% in the last 24 hours and down -10.84% over the past month.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
See More
Previous Close:
$1.9999
Open:
$2
24h Volume:
21,162
Relative Volume:
2.79
Market Cap:
$9.69M
Revenue:
$2.35M
Net Income/Loss:
$-2.56M
P/E Ratio:
-3.8672
EPS:
-0.4396
Net Cash Flow:
-
1W Performance:
-12.37%
1M Performance:
-10.84%
6M Performance:
-29.75%
1Y Performance:
-9.33%
1-Day Range:
$1.70
$2.00
1-Week Range:
$1.70
$2.0848
52-Week Range:
$1.59
$5.96
Immuron Limited Adr Stock (IMRN) Company Profile
Compare IMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
1.70 | 9.69M | 2.35M | -2.56M | 0 | -0.4481 |
|
VRTX
Vertex Pharmaceuticals Inc
|
402.70 | 103.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
712.33 | 78.28B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
615.00 | 36.77B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.31 | 30.35B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.95 | 27.32B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immuron Limited Adr Stock (IMRN) Latest News
Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event - GlobeNewswire Inc.
Immuron to Present at Q4 Virtual Investor Summit: Gut Disease Pipeline Showcase | IMRN Stock News - StockTitan
Immuron Travelan® continued strong sales growth - Quantisnow
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study - The Manila Times
IMRNImmuron Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Immuron: US FDA provides favourable feedback ahead of investigational new drug application for IMM-529 - Proactive Investors Australia
Immuron Plans Phase 2 Trial for IMM-529 following FDA review - Markets Insider
Immuron Plans Phase 2 Trial for IMM-529 following FDA review | Daily Guardian - Daily Guardian Canada
Immuron secures new US DoD research award - Investing.com
Immuron secures new US DoD research award By Investing.com - Investing.com Australia
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire Inc.
Treasuries slip, dollar firm as markets grapple with US politics By Reuters - Investing.com
Curtiss Wright CEO Lynn M Bamford buys $10.2k in stock By Investing.com - Investing.com India
Immuron CEO to present at Sharewise investor event By Investing.com - Investing.com
Immuron to raise up to $2M as part of an ATM equity offering (NASDAQ:IMRN) - Seeking Alpha
Immuron secures around US$2 million in funding after lodging Form F-3 and ATM prospectus with US SEC By ... - Investing.com
Immuron requests pre-IND meeting for IMM-529 with FDA filing - Markets Insider
Immuron files pre-investigational new drug US FDA application for superbug fighting IMM-529 - Proactive Investors Australia
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Markets Insider
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.34% - Investing.com India
Immuron stock surges after mid-stage data for Travelan - Seeking Alpha
Immuron Limited Announces Participation in the LD Micro Invitational XIII - The Kingston Whig-Standard
Immuron US DoD Naval Medical Research Center responds to - GlobeNewswire
Immuron’s Technology Platform of Treatments in the Age of the Coronavirus Outbreak - GlobeNewswire
Immuron Limited Trade Ideas — NASDAQ:IMRN - TradingView
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.33% - Investing.com
Immuron Limited Issues Correction to Misleading Halt Announcement Headline - GlobeNewswire
Pharma & Biotech - Proactive Investors USA
Immuron Limited Adr Stock (IMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
1.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):